Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pain Pract ; 23(4): 447-458, 2023 04.
Article in English | MEDLINE | ID: mdl-36597700

ABSTRACT

AIMS: We aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. CONTENT: Chronic pain is a common and complex problem, with an unknown etiology. Psychedelics like lysergic acid diethylamide (LSD) and psilocybin, may play a role in the management of chronic pain. Through activation of the serotonin-2A (5-HT2A) receptor, several neurophysiological responses result in the disruption of functional connections in brain regions associated with chronic pain. Healthy reconnections can be made through neuroplastic effects, resulting in sustained pain relief. However, this process is not fully understood, and evidence of efficacy is limited and of low quality. In cancer and palliative related pain, the analgesic potential of psychedelics was established decades ago, and the current literature shows promising results on efficacy and safety in patients with cancer-related psychological distress. In other areas, patients suffering from severe headache disorders like migraine and cluster headache who have self-medicated with psychedelics report both acute and prophylactic efficacy of LSD and psilocybin. Randomized control trials are now being conducted to study the effects in cluster headache Furthermore, psychedelics have a generally favorable safety profile especially when compared to other analgesics like opioids. In addition, psychedelics do not have the addictive potential of opioids. IMPLICATIONS: Given the current epidemic use of opioids, and that patients are in desperate need of an alternative treatment, it is important that further research is conducted on the efficacy of psychedelics in chronic pain conditions.


Subject(s)
Chronic Pain , Cluster Headache , Hallucinogens , Neoplasms , Humans , Hallucinogens/therapeutic use , Psilocybin/therapeutic use , Lysergic Acid Diethylamide/therapeutic use , Chronic Pain/drug therapy , Neoplasms/complications , Neoplasms/drug therapy , Randomized Controlled Trials as Topic
3.
J Immunother ; 43(3): 93-94, 2020 04.
Article in English | MEDLINE | ID: mdl-32011418

ABSTRACT

Nivolumab is an anti-programmed death-1 inhibitor used in the treatment of cancer. Nivolumab has recently been approved as an adjuvant treatment for patients with stage IIIB, IIIC, and completely resected stage IV melanoma in the Netherlands. Despite the promising results of nivolumab, there is a wide variation in toxic side effects. A nivolumab-induced bilateral vocal cord paralysis (BVCP) was not reported. In this case, we present a nivolumab-induced BVCP. A 75-year-old man received nivolumab as adjuvant therapy for stage III melanoma. After the first cycle of nivolumab, this patient developed immune-related hepatitis and colitis. During admission, the patient became respiratory insufficient as a result of a BVCP. This case report describes immune-related hepatitis, colitis, and BVCP after the first cycle of nivolumab in the treatment of stage IIIb melanoma. Follow-up has not yet shown improvement in the mobility of the vocal cords.


Subject(s)
Immune Checkpoint Inhibitors/adverse effects , Nivolumab/adverse effects , Vocal Cord Paralysis/diagnosis , Vocal Cord Paralysis/etiology , Aged , Biomarkers , Humans , Immune Checkpoint Inhibitors/therapeutic use , Laryngoscopy , Male , Neoplasms/complications , Neoplasms/drug therapy , Neoplasms/pathology , Nivolumab/therapeutic use , Radiography , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...